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A B S T R A C T
Background
Sickle cell disease (SCD), one of the most common inherited disorders, is associated with vaso-occlusive pain episodes and haemolysis
leading to recurrent morbidity, hospital admissions and work or school absenteeism. The crises are conventionally treated with opioids,
non-opioids and other adjuvants with the risk of developing complications, addictions and drug-seeking behaviour. DiEerent non-
pharmacological treatments, such as transcutaneous electrical nerve stimulation (TENS) have been used for managing pain in other painful
conditions. Hence, the eEicacy of TENS for managing pain in SCD needs to be reviewed.
Objectives
To assess the benefits and harms of TENS for managing pain in people with SCD who experience pain crises or chronic pain (or both).
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Register, comprising of references identified
from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
We also searched online trial registries and the reference lists of relevant articles and reviews.
Date of the last search: 26 Febraury 2020.
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs, where TENS was evaluated for managing pain in people with SCD.
Data collection and analysis
Two review authors independently assessed the eligibility of the trials identified by the literature searches according to the inclusion
criteria. Two review authors then independently extracted data, assessed for risk of bias using the Cochrane standard tool and rated the
quality of evidence using the GRADE guidelines.
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Main results
One double-blind cross-over RCT with 22 participants with SCD (aged 12 to 27 years) was eligible for inclusion. Following stratification into
four pain crises severity grades, participants were then randomised to receive TENS or placebo (sham TENS). The trial was concluded aJer
60 treatment episodes (30 treatment episodes of each treatment group).
There is a lack of clarity regarding the trial design and the analysis of the cross-over data. If a participant was allocated to TENS treatment
for an episode of pain and subsequently returned with a further episode of a similar degree of pain, they would then receive the sham TENS
treatment (cross-over design). For those experiencing a pain episode of a diEerent severity, it is not clear whether they were re-randomised
or given the alternate treatment. Reporting and analysis was based on the total number pain events and not on the number of participants.
It is unclear how many participants were crossed over from the TENS group to the sham TENS group and vice versa. The trial had a high
risk of bias regarding random sequence generation and allocation concealment; an unclear risk regarding the blinding of participants and
personnel; and a low risk regarding the blinding of the outcome assessors and selective outcome reporting.
The trial was small and of very low quality; furthermore, given the issue with trial design we were unable to quantitatively analyse the data.
Therefore, we present only a narrative summary and caution is advised in interpreting the results. In relation to our pre-defined primary
outcomes, the included trial did not report pain relief at two to four weeks post intervention. The trial authors reported that no diEerence
was found in the changes in pain ratings (recorded at one hour and four hours post intervention) between the TENS and the placebo groups.
In relation to our secondary outcomes, the analgesic usage during the trial also did not show any diEerence between groups. Given the
quality of the evidence, we are uncertain whether TENS improves overall satisfaction as compared to sham TENS. The ability to cope with
activities of daily living was not evaluated. Regarding adverse events, although one case of itching was reported in the TENS group, the site
and nature of itching was not clearly stated; hence it cannot be clearly attributed to TENS. Also, two participants receiving 'sham' TENS
reported a worsening of pain with the intervention.
Authors' conclusions
Since we have only included one small and very low-quality trial, with a high risk of bias across several domains, we are unable to conclude
whether TENS is harmful or beneficial for managing pain in people with SCD. There is a need for a well-designed, adequately-powered,
RCT to evaluate the role of TENS in managing pain in people with SCD.
P L A I N   L A N G U A G E   S U M M A R Y
Transcutaneous electrical nerve stimulation (TENS) for managing pain in people with sickle cell disease
Review question
What is the role of transcutaneous electrical nerve stimulation (TENS) in managing pain in people with sickle cell disease (SCD)? What are
the adverse eEects of TENS in people with SCD?
Background.
SCD is an inherited disorder aEecting red blood cells. These cells contain haemoglobin which transports oxygen. The diseased red blood
cells block the blood vessels and result in a diminished blood supply, leading to less oxygen reaching aEected organs and causing episodes
of pain and organ damage. Severe pain requires medication and even hospitalisation. Prescribed painkillers can have several side eEects,
including drug dependency. Hence researchers are looking for options other than drug treatments for people with SCD.
TENS is a small battery-powered electro-medical device that produces low-voltage current and is used for pain relief in various painful
conditions. It is safe, inexpensive and easy to use. Since mixed responses have been seen in diEerent painful conditions, we felt the need
to produce a Cochrane Review with a comprehensive search, to determine the eEect of TENS for managing pain in people with SCD.
Search date
The evidence is current to 26 February 2020.
Study characteristics
We searched for well-designed trials to see the eEect of TENS compared to 'sham' TENS in people with SCD for relieving pain, reducing
the intensity of pain, reducing the frequency of pain episodes, making a diEerence to the use of painkillers, improving quality of life and
for assessing any adverse eEects.
We only found one trial (22 participants aged between 12 and 27 years). The participants were graded into four groups according to how
severe their pain was. On the first visit, the participants from diEerent groups were chosen randomly to receive either TENS or ‘sham’
TENS treatment. For a further crisis of the same severity participants were given the alternative intervention to the first one. For those
experiencing a pain episode of a diEerent severity, it is not clear which treatment they were given.
Neither the participant nor the researcher were aware of which treatment was received.
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Key results
30 episodes (across 22 participants) of TENS treatment and 30 of 'sham' TENS treatment were analysed. Due to low-quality data and issues
with the trial design, we can only report in a descriptive way without any formal analysis. Caution should be used in interpreting these
results. In the included trial no diEerence was found in the rating of pain on a scale of 1 to 10 at the end of one hour and four hours between
the TENS and 'sham' TENS treatment groups. There was no diEerence between groups as to how much pain medication was used. Given
the very low quality of the evidence, we are also uncertain whether TENS improves overall satisfaction as compared to 'sham' TENS. A
minor adverse eEect of itching was reported by only one person receiving TENS, whereas two people receiving 'sham' TENS reported a
worsening of pain with the intervention. Since there is only one included trial with very low-quality evidence, we cannot state whether
TENS makes any diEerence to managing pain in people with SCD.
Quality of the evidence
The trial publication did not clearly report how the randomised list for allocating the participants to the two treatment groups was
generated, therefore, we assessed this as having a high risk of bias. The reporting and analysis was based on only the total number pain
events and not the number of people reporting pain episodes. It is unclear from this report how many participants were crossed over from
TENS to 'sham' TENS treatment group. The first treatment may have an eEect on the subsequent treatment and there is no clear data
regarding the cross over process from one treatment group to the other. Hence we conclude that the trial has a high risk of bias and the
results are hard to interpret.
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease (Review)





























































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.
TENS compared with placebo (sham TENS) for SCD




Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes










Pain relief (percentage relief com-
pared to baseline)
Follow-up: 2 to 4 weeks post inter-
vention
This outcome was not measured.  
Pain intensity (visual analogue
score from 0 to 10 where 10 is the
most severe pain)
Follow-up: up to 4 hours post inter-
vention
No significant difference in pain intensity was seen between the TENS






The unit of analy-
sis for this outcome
was pain crises so
1 participant may
have had more than
1 episode. The total
number of episodes
included in the
analysis was 25 in
the TENS group and
30 in the placebo
group.
Frequency of pain episodes This outcome was not measured. Each episode of pain
was treated inde-
pendently as a new
episode. Total num-
























































































































































Change in consumption of anal-
gesics (number of participants re-
quiring analgesia)
Follow-up: up to 4 hours post inter-
vention
There was no significant difference between the TENS group and the
placebo group in the number of people requiring analgesia up to one
hour post treatment (TENS 14 %; sham TENS 25 %, X2 = 1.07, P = 0.30).
There was no significant difference between the TENS group and the
placebo group in the number of people requiring analgesia up to four









Change in QoL This outcome was not measured. Participants were
asked to rate
whether the treat-
ment was helpful or
harmful but this re-
lated directly to the
pain.
Change in ability to cope with ADL This outcome was not measured.  
Adverse effects
Follow-up: up to 1 hour and 4
hours post treatment.
There was one case of itching reported in the TENS group but it was un-
clear whether it was related to the treatment. 2 participants in the place-





No data were pro-




*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
a. Downgraded twice because of high risk of bias within the included trial. The randomisation process was unclear and when participants entered the trial for a second or
third episode, they were allocated to the alternative treatment from their original allocation. Although the trial authors described their method of blinding participants to the
intervention, it is unclear how successful this was given that the TENS would give a tingling sensation and the sham TENS would not. There were also issues around selective
reporting of outcomes and a lack of clarity around allocation of each pain episode to a treatment arm.
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B A C K G R O U N D
Description of the condition
Please refer to the glossary for the explanation of clinical terms
(Appendix 1).
Sickle cell disease (SCD) encompasses a host of genetically
inherited disorders in which red blood cells become increasingly
deformed and friable, causing vaso-occlusion and haemolysis. This
disease is one of the most common, severe, single gene mutation
(monogenic) disorders (Weatherall 2001).
The disease is most prevalent in sub-Saharan Africa, aEecting
an estimated 230,000 children born regionally every year -
accounting for 80% of the total global incidence (David 2010).
In the USA, it aEects around 100,000 people, predominantly
those of African descent. The disease occurs in about one in
every 500 African-American births and one in every 1000 to 1400
Hispanic-American births. Approximately two million Americans,
or one in 12 African Americans, carry the sickle cell allele (WHO
2015). This geographical predominance corresponds to an adaptive
advantage: heterozygous carriers (sickle cell trait) are naturally
resistant to infection by the endemic Plasmodium falciparum (P
falciparum) malarial parasite (Barbedo 1974).
The vaso-occlusive crisis (VOC) is the hallmark of the disease and
is oJen unpredictable, varies in intensity, duration, location and
severity, and can be precipitated by known and unknown factors
(Ballas 2005). Vaso-occlusive pain episodes are the most common
cause of recurrent morbidity, hospital admissions and work or
school absenteeism in people with SCD (Platt 1991). Approximately
90% of hospital admissions of people with SCD are for treating
acute pain (Brozovic 1987). Hypoxia, dehydration, acidosis, cold
exposure and strenuous exercise also can lead to sickling of red
blood cells leading to an acute painful episode.
Nociceptive sickle cell pain may be acute recurrent painful crises,
chronic pain syndromes and neuropathic pain. The acute painful
crisis evolves through prodromal, initial, established and resolving
phases (Ballas 2012). Chronic sickle cell pain may be due to
avascular necrosis and leg ulcers or intractable pain without any
obvious signs. Chronic pain is usually associated with emotional
distress, behavioural dysfunction, family stress, financial concern,
frequent visits to healthcare providers, heavy use of analgesic
medications and fear (Ballas 2005).
Treatment aims for SCD are to relieve pain, prevent infections
and manage complications (Stinson 2003). Despite being the main
source of discomfort for people with SCD, therapies for pain crises
are not definitive. Pharmacotherapies involve opioids, non-opioids
and adjuvants. Non-opioids (e.g. acetaminophen, nonsteroidal
anti-inflammatory drugs (NSAIDs) tramadol and corticosteroids)
have a 'ceiling eEect' beyond which they are no longer eEective, and
NSAIDs and corticosteroids have well-known complications such
as haemostasis, acute renal failure, congestive heart failure when
overused (Niscola 2009). Thus opioids are frequently employed, as
they have fewer systemic eEects. However, their use is plagued with
reports of addiction, tolerance and drug-seeking behaviour (Neville
2011). Moreover, opioids may contribute to the development
of acute chest syndrome during an acute sickle cell pain crisis
(Buchanan 2005).
These factors have motivated clinicians and researchers
worldwide to embrace a multidisciplinary approach towards
pain management in people with SCD, with a focus on
including non-pharmacological interventions. According to the
recommendations of the American Pain Society, pharmacological
treatments for SCD should be complimented by psychological,
behavioral, and physical modalities (American Pain Society
Guidelines 1999).
Description of the intervention
As defined by the American Physical Therapy Association, TENS
is the application of electrical stimulation to the skin for
pain control. It is non-invasive, inexpensive, safe, and easy to
use; a small battery-powered device applies an electric current
via two or more non-invasive skin electrodes to stimulate
underlying nerves and thus reduce pain perception. It can be
applied with diEerent frequencies, varying from low (< 10 Hz)
to high (> 50 Hz). Intensity can also vary with low-intensity
stimulation producing a sensation alone, while high-intensity
stimulation triggers muscle contraction, and hence movement.
Low-frequency TENS is usually given at high-intensity (producing
motor contraction and sensation), while high-frequency TENS is
given at lower intensities (producing both sensation and muscle
contraction) (DeSantana 2008). Conventional TENS has a high-
stimulation frequency (40 Hz to 150 Hz) and low intensity between
10 mA to 30 mA. The pulse duration is short (up to 50 microseconds).
The onset of analgesia with this setup is virtually immediate. Pain
relief lasts while the stimulus is turned on, but it usually abates
when the stimulation stops. In acupuncture like settings, the TENS
unit delivers low frequency stimulus trains at 1 Hz to 10 Hz, at a high
stimulus intensity, close to the tolerance limit of the individual. This
method is uncomfortable and is oJen considered for those who do
not respond to conventional TENS. Pulsed (burst) TENS uses low-
intensity stimuli firing in high-frequency bursts, but does not have
any added advantage over the conventional method.
Over the last 40 years, TENS has been evaluated for
the management of pain in numerous conditions, including
fibromyalgia (Sunshine 1996) rheumatoid arthritis, osteoarthritis,
post-caesarean pain, lower back pain (Milne 2004) neck pain and
numerous other causes. While reviews report that evidence on
the eEicacy of TENS is inconclusive, magnetic resonance imaging
(MRI) studies implicate central pain signal modulation indicating
a central action (Kocyigit 2012). There are contraindications for
the use of TENS. These include use during pregnancy, as it may
induce premature labour, as well as application over the carotid
sinuses, due to the risk of acute hypotension through a vasovagal
reflex. In addition to these, it should not be placed over the anterior
neck, because laryngospasm due to laryngeal muscle contraction
may occur, the electrodes should not be placed in an area of
sensory impairment, where the possibility of burns exists and a
TENS unit should be used cautiously in individuals with a spinal
cord stimulator or an intrathecal pump.
How the intervention might work
A variety of mechanisms for the analgesic action of TENS have
been suggested, including presynaptic inhibition in the dorsal horn
of the spinal cord, endogenous pain control via endorphins, and
direct inhibition of nerve excitation and restoration of aEerent
input (Kaye 2015). These produce a host of responses, including
sensation, movement (muscle contraction), and pain relief. In
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease (Review)
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people with SCD, vaso-occlusion leads to secondary tissue injury
which generates several major pain mediators like interleukin-1,
bradykinin which in turn sensitise peripheral nerve endings and
facilitate the transmission of painful stimuli along A-δ and C
fibres that reach the cerebral cortex via the spinal cord and the
thalamus (Ballas 2005). This partly corresponds to the 'gate control
theory' (Melzack 1965) for the mechanism of analgesia produced by
TENS where the 'open gate' between C fibres and T cells which allow
pain transmission centrally is closed by the electrical stimulation to
the skin provided by the TENS instrument.
Why it is important to do this review
Over recent years, although considerable knowledge has been
gained on the pathophysiological mechanisms of pain and the
pharmacogenetics of analgesics (including opioids) there has been
not much progress in the clinical management of sickle cell pain.
Many adults with SCD still face accusations, assumptions and
disbelief about their painful condition which is oJen wrongly
perceived by some healthcare providers as drug-seeking behaviour
(Ballas 2014). Mismanagement of pain in SCD may lead to serious
psychosocial and physiological consequences, such as depression,
low self esteem, anxiety and reduced participation in social
activities, resulting in chronic pain interspersed with episodes
of acute exacerbations (Smith 2005). Hence, organisations such
as the American Pain Society recommended that pharmacologic
treatment for SCD should be complemented by complementary
and alternative medicine.
Cochrane Reviews on TENS for specific chronic pain conditions
such as rheumatoid arthritis, osteoarthritis, have suggested that
TENS is more eEective than placebo (sham) TENS, although
methodological weaknesses in randomised controlled trials (RCTs)
have sometimes hindered definitive conclusions (Bennett 2011;
Brosseau 2003; Johnson 2010; Rutjes 2009). Studies carried out on
the eEect of TENS on neck pain suggested that active TENS may
be more eEective than placebo TENS (Kroeling 2013). A systematic
review on the eEect of TENS on cancer pain in adults suggested
bone pain on movement may improve in a cancer population on
application of TENS, but most of the results remained inconclusive
due to a limited number of RCTs included in the review (Hurlow
2012).
Most reviews of TENS therapy are inconclusive at present, which
is why a standardised, rigorous search and a Cochrane Review are
required in this disease area. This issue is further compounded
by the practical need to manage the acute pain crises, as well
as chronic pain conditions, experienced by millions of people
with SCD worldwide. Current pharmacological therapies produce
too many unacceptable side eEects, and as already stated,
recommendations encourage the use of non-pharmacological
methods in SCD pain management. A Cochrane Review of
the current evidence regarding the eEectiveness of TENS as a
complementary therapy for managing pain in people with SCD
will allow health professionals and researchers make informed
decisions about the use of this treatment.
O B J E C T I V E S
To assess the benefits and harms of TENS for managing pain in
people with SCD who experience pain crises or chronic pain (or
both).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include RCTs and quasi-RCTs (if suEicient evidence
was provided to demonstrate that the treatment and control
groups are similar at baseline).
In reference to cross-over trials, as we were currently unaware of
the long-term eEects of these interventions, we were unable to
determine whether the eEects of the first intervention will interfere
with those of the second. In order to avoid introducing this bias into
the analysis, we planned to include only first-arm data from cross-
over trials, when available.
Types of participants
People with known SCD (SS, SC, Sβ⁺ and Sβ0, proven by
electrophoresis and sickle solubility test, with family studies or DNA
tests as appropriate) of all ages and both sexes, in any setting.
Types of interventions
We included all standard modes of TENS, biphasic or monophasic
electrical current delivered in pulses in high intensity or high
frequency, low intensity or low frequency, or other standard modes
that produce perceptible sensation at the area of application. We
excluded other modes of electrotherapy, e.g. TENS delivered in
barely perceptible intensity.
Eligible comparisons are:
• TENS with conventional treatment (e.g. analgesics) versus
conventional treatment alone;
• TENS versus placebo (sham TENS);
• TENS versus other non-pharmacological modalities for
managing pain.
We did not plan to compare diEerent intensities and frequencies of
TENS.
Placebo (sham TENS) devices may look exactly the same as active
TENS devices, but are deactivated and produce no current or may
produce a brief period of stimulation at the beginning which fades
out later. Due to the lack of perceptible stimulation in sham TENS,
the blinding of participants to the mode of treatment is almost
impossible (Sluka 2013) and this represents a risk of bias to all
sham-controlled trials of TENS (Gibson 2015).
Types of outcome measures
Primary outcomes
1. Pain relief *
2. Pain intensity (as assessed by visual analogue pain scale score
(VAS) or other validated assessment tools for measuring pain
intensity during the use of TENS)
3. Frequency of pain episodes
* We aimed to present data at two to four weeks and four weeks post
intervention. For long-term usage (e.g. for a period of one month or
more) we planned to consider the outcome measures up to three
months. We also considered pain relief as moderate (at least 30%
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pain relief over baseline) or substantial (at least 50% pain relief over
baseline) as defined by IMMPACT guidelines (Dworkin 2008).
Secondary outcomes
1. Changes in consumption of analgesic and opioids during pain
episodes
2. Changes in quality of life (QoL) (as measured by a validated
scale)
3. Ability to cope with the activities of daily living (ADL)
4. Adverse eEects of the intervention
Search methods for identification of studies
We searched for all relevant published and unpublished trials
without restrictions on language, year or publication status.
Electronic searches
The Cochrane Cystic Fibrosis and Genetic Disorders Group's
Information Specialist conducted a search of the Group's Cystic
Fibrosis Trials Register for relevant trials using the following terms:
(sickle cell OR (haemoglobinopathies AND general)) AND TENS).
The Haemoglobinopathies Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated each new issue of  the Cochrane
Library) and weekly searches of MEDLINE. Unpublished work
is identified by searching the abstract books of five major
conferences: the European Haematology Association conference;
the American Society of Hematology conference; the British Society
for Haematology Annual Scientific Meeting; the Caribbean Health
Research Council Meetings; and the National Sickle Cell Disease
Program Annual Meeting. For full details of all searching activities
for the register, please see the relevant section of the  Cochrane
Cystic Fibrosis and Genetic Disorders Group's website.
Date of the most recent search of the Cystic Fibrosis and
Genetic Disorders Group's Haemoglobinopathies Trials Register: 26
February 2020.
We searched the following databases (Appendix 2):
• PubMed (www.ncbi.nlm.nih.gov/pubmed, 1946 to 04 April
2017);
• Embase Ovid (1974 to 16 October 2017).
In addition, we also searched the following trial registries and other
resources (Appendix 2):
• US National Institutes of Health Ongoing Trials Register,
ClinicalTrials.gov (clinicaltrials.gov/; searched on 04 September
2017);
• International Standard Randomised Controlled Trials Number
(www.isrctn.com/; searched on 04 September 2017);
• World Health Organisation International Clinical Trials Registry
Platform (apps.who.int/trialsearch/; searched on 04 September
2017);
• Google Scholar (scholar.google.co.uk/; searched on 04
September 2017).
Regarding our use of Google Scholar, we performed a Google
Scholar Advanced search, sorted the results based on relevance,
and screened the first 100 search results for relevant trials. For




We checked the bibliography of the included trial for further
references to relevant trials. We also searched research papers
which cannot be directly included in this review (observational
studies, systematic and narrative reviews, conference reports, etc.)
for the citations of relevant trials which may have been eligible for
inclusion. These papers were then sought and assessed for possible
inclusion in the review.
Authors and organisations
We contacted the trial authors who have conducted prominent
research in the relevant field regarding their ongoing trials or other
relevant papers which may be eligible for inclusion. We contacted
the following organisations for further information:
• NCCIH formerly known as NCCAM;
• Foundation for Alternative and Integrative Medicine;
• American Alternative Medical Association;
• The Complementary and Natural Healthcare Council;
• International Alternative Medical Association;
• The Association for Applied Psychophysiology and Biofeedback
(formerly the Biofeedback Society of America).
Grey literature
Regarding grey literature, research has shown that published
studies oJen overestimate outcomes, compared to grey literature
articles (Hopewell 2007). Moreover, exclusion of grey literature can
result in systematic error, thus seriously threatening the validity of
a systematic review (McAuley 2000). Therefore, to avoid this risk
of publication bias, we searched grey literature databases in our
attempt to identify relevant trials and authors from conference
proceedings. We searched the following databases (recommended
in the Cochrane Handbook For Systematic Reviews of Interventions)
for unpublished reports or articles which may be appropriate for
inclusion in this systematic review (Higgins 2011a):
• OpenGrey (www.opengrey.eu/: searched on 04 September
2017);
• PsychEXTRA (www.apa.org/psycextra/; searched on 04
September 2017);
• the Grey Literature Report (http://greylit.org/; searched on 04
September 2017);
• the Agency for Healthcare Research and Quality
(www.ahrq.gov/; searched on 04 September 2017);
• MedNar (http://mednar.com/mednar/desktop/en/search.html;
searched on 04 September 2017).
For details of our search strategies, please refer to the appendices
(Appendix 2).
Data collection and analysis
Selection of studies
Two review authors (SP, MG) independently assessed the eligibility
of the trials identified by the literature searches by completing
a trial selection form that was designed in accordance with the
inclusion criteria. Each author independently evaluated each title
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for inclusion. If we did not find the relevant information in the
abstract, we tried to retrieve the relevant full text, report(s). Both
authors approved the inclusion of the trial in the review. In the
case of any discrepancy related to eligibility, a third author (SKB)
would have arbitrated, however, no such discrepancy occurred.
We tabulated the excluded trials under 'Characteristics of excluded
studies' and gave reasons for the exclusion. The review authors
were not blinded to the identity of the trial authors, institutions or
trial results during their assessments. We also produced a PRISMA
chart to illustrate the trial selection process (Figure 1).
 
Figure 1.   Study flow diagram.
 
Data extraction and management
Two review authors (SP, SM) independently and simultaneously
extracted data from the selected articles and this was verified by
two other review authors with an aim to resolve any disagreements
by discussion and consensus.
We extracted data using a standardised, pre-tested data extraction
form. The review authors designed the data extraction form
together and pilot tested it using a sample RCT and a quasi-RCT to
ensure practical functionality.
We extracted the following information from the included trial.
1. Trial characteristics and source
• Trial identifier (ID) - created by the review author
• Report ID - created by the review author
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease (Review)














• Trial time and duration
• Setting
• Randomisation
• Allocation sequence concealment
• Type of blinding used





• Age and gender of participants
4. Interventions (TENS and variants)
• Total number of intervention groups
For each intervention and comparison group of interest
• Electrode position
• Professional discipline of the clinician delivering TENS
• Frequency and intensity of the electrical current applied
through the TENS device
• Frequency of administration




• Units of measurement (if relevant)
• For scales, state upper and lower limits, and the interpretation
of the scale
6. Results
• Number of participants allocated to each intervention group
For each outcome of interest
• Sample size
• Missing participants
• Summary data for each intervention group (mean and standard
deviation (SD) for continuous data, 2 x 2 contingency table for
dichotomous data, etc.)
We had obtained two reports of the same trial by the same authors.
However, since the outcomes were the same in both, we considered
the later report.
Assessment of risk of bias in included studies
Two review authors (RD, SM) independently assessed the risk of
bias of the included trial by using the criteria outlined in chapter 8
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b).
We assessed each trial according to the following six components.
1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Masking (blinding) of participants and personnel (performance
bias), and masking of outcome assessor.
4. Incomplete outcome data (attrition bias) through withdrawals,
dropouts and protocol deviations; and
5. Selective reporting bias
6. Other bias
We also assessed for any other sources of bias as reported in
the Cochrane Handbook for Systematic Reviews of Interventions
(bias related to the specific trial design, early or abrupt end of
trials, fraudulent trials) (Higgins 2011b). For each of the mentioned
components, we assigned judgements of either low, unclear or high
risk of bias.
We recorded the results in the standard table provided in the
Review Manager soJware (RevMan 2014), and summarised the
findings in a 'Risk of bias' table or graph. We resolved all concerns
or issues by discussion with a third review author (ALA). We also
addressed the implications of the 'Risk of bias' assessment in the
discussion section.
Measures of treatment e>ect
For future updates of this review, if we include more trials, we plan
to analyse and present dichotomous data (e.g. improvement in
pain rating, analgesic usage, and overall satisfaction with TENS)
using the risk ratios (RR) with 95% confidence intervals (CIs). We
will report adverse eEects of the intervention with 99% CIs to avoid
errors due to multiple statistical testing. We will analyse continuous
data (e.g. pain scores) using the mean diEerence (MD) and 95% CIs.
We will also calculate the standardised MD (SMD) if diEerent scales
of measurement have been used.
We will present count data (e.g. frequency of pain episodes) as the
MD, by comparing the diEerence in the mean number of events
in the intervention group as compared to the control group and
present them as rate ratio with 95% CI in case of rare events.
If we identify trials with multiple treatment arms, we will only
include those treatment arms whose parameters are minimally
diEerent from the other included trials.
In this current version of the review, since no meta-analyses were
possible, we have presented a narrative summary.
Unit of analysis issues
We planned to use individuals with SCD as the unit of analysis in
this review.
Regarding cross-over trials, as we are currently unaware of the long-
term eEects of these interventions, we are unable to determine
whether the eEects of the first intervention will interfere with those
of the second. In order to avoid introducing this bias into the
analysis, we aimed only to include first-arm data from cross-over
trials, when available. The included trial did not present first-arm
data and we were unable to analyse any data from this trial, also
whilst reporting on 22 participants, data on 60 treatment episodes
were presented (30 for each treatment group). We have therefore
only reported on the included trial in a narrative way.
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For future updates, we intend to report any included cluster-
randomised trials separately.
Dealing with missing data
We contacted the trial authors and requested access to the missing
data regarding methods, participants, interventions and outcomes.
The lead investigator on the included trial provided the original
protocol (Wang 1988).
Assessment of heterogeneity
For future updates, if more trials are included in the review, in
order to deal with clinical heterogeneity, we will pool trials that
examine similar interventions. We will perform separate analyses
for TENS compared to conventional treatment and TENS compared
to placebo TENS or other non-pharmacological treatment. We will
use the Chi2 test for assessing heterogeneity (significance level: P
< 0.1). We will quantify the degree of heterogeneity using the I2
statistic (Deeks 2008). The guidelines for interpretation of the I2
values will be as follows.
• 0% to 40% indicates unimportant levels of heterogeneity
• 30% to 60% indicates moderate heterogeneity
• 50% to 90% indicates substantial heterogeneity
• 75% to 100% indicates considerable heterogeneity
We will also consider a visual inspection of the forest plot to identify
whether CIs overlap.
Assessment of reporting biases
For the included trial, we compared the protocol provided by the
author with the published report (Wang 1988). We also requested
and obtained the raw data for comparison with the published data.
However, the raw data did not provide us with either the baseline
pain score or the SD. In the absence of any other eligible trial, we
could not impute the SD, hence we were unable to conduct any
paired analysis.
Although this version of the review does not include trials from
the grey literature, we do anticipate that these may be included
in future updates. Therefore, it is particularly important for us to
conduct an assessment of publication bias. For future updates,
if we identify at least 10 trials for inclusion in a meta-analysis,
we will explore potential publication bias by generating a funnel
plot and performing Egger’s test to determine the degree of
asymmetry (Egger 1997). If the included trials diEer in sample
size then we will visually inspect the funnel plots to explore the
possibility of reporting biases. We will interpret the results of
Egger’s test cautiously due to the presence of many limitations in
quantifying possible reporting biases (Moore 2008). We will address
the implications of the publication bias assessment on the review
findings in the discussion section.
Data synthesis
We synthesised the quantitative data compiled using the data
extraction form but did not undertake any meta-analyses due
to issues of the trial design and reporting. We will calculate
the I2 statistic to determine statistical heterogeneity, and thus
determine whether we will use a fixed-eEect model (unimportant
heterogeneity), or a random-eEects model (at least moderate
heterogeneity) for the meta-analysis (DerSimonian 1986). The
results of the meta-analysis will be reported as pooled eEect
estimates, stated with 95% CIs and illustrated graphically in a forest
plot.
Subgroup analysis and investigation of heterogeneity
In future, if we identify substantial (or higher) statistical
heterogeneity we plan the following subgroup analysis
investigating the possible eEect of TENS based on:
• age groups (below 18 years of age, 18 years and over);
• gender (male, female);
• stimulation parameters (e.g. high stimulation frequency with
low intensity, low frequency with a high stimulus intensity);
• frequency of administration of TENS (e.g. daily or not on a daily
basis);
• duration of treatment with TENS (e.g. 30-minute sessions and
under or more than 30 minutes).
Sensitivity analysis
If appropriate we will assess the robustness of our findings
by performing sensitivity analyses according to Cochrane
recommendations (Deeks 2011). If there are suEicient comparable
trials, i.e. 10 or more, we will perform sensitivity analyses to
study the eEect of excluding trials with high risks of bias due
to inadequate allocation of concealment, blinding, randomisation
method or level of dropouts. Furthermore, we will also consider the
impact of using a fixed-eEect model compared to a random-eEects
model.
Summary of findings table
Even though there are limited data available from the included trial
(with a high risk of bias across several domains), we have produced
a summary of findings table (Summary of findings for the main
comparison).
We have used the GRADE approach to create a 'Summary of
findings' table, as suggested in chapters 11 and 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2011a; Schünemann 2011b). The table presents the trial population
and setting, the type of intervention and control group, the
outcome measures listed below and an assessment of the evidence
quality (as measured by the GRADE approach).
We used the GRADE approach to rate the quality of the evidence
as 'high', 'moderate', 'low', or 'very low' using the five GRADE
considerations.
1. Risk of bias: serious or very serious
2. Inconsistency: serious or very serious
3. Indirectness: serious or very serious
4. Imprecision: serious or very serious
5. Publication bias: likely or very likely
We generated a 'Summary of findings' table for the 'TENS compared
to placebo' comparison with the following outcomes (if data
available). For future updates, if more comparisons are included,
we plan to produce multiple tables.
• Pain relief
• Pain intensity as assessed by VAS or any other validated pain
score
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• Frequency of pain episodes
• Changes in consumption of analgesics and opioids during pain
episodes
• Changes in QoL (as measured by a validated scale)
• Changes in ability to cope with the ADL
• Adverse eEects of the intervention
R E S U L T S
Description of studies
Results of the search
In the search from the Cystic Fibrosis and Genetic Disorders Group’s
Haemoglobinopathies Trials Register, the Group's Information
Specialist identified two references, both pertained to the same
trial. We further identified eight references from a search of
PubMed; 98 references from Google Scholar (Advanced Search),
one reference from a Clinical Trials Registry; eight references
from a search of the Agency for Healthcare Research and Quality
(AHRQ) database; and 180 references from a search of MedNar.
We identified no relevant references from searches of online trial
registries.
As illustrated in an additional figure, aJer removing duplicates, we
screened 266 references (Title/Abstract), of which we excluded 243
references (Figure 1). We reviewed the full texts of 23 remaining
references and excluded 21 trials and included one trial (two
references) (Wang 1988).
Included studies
We included one trial in this review (Wang 1988).
Study design
The included trial was a double-blind RCT; it was conducted
in St. Jude Children's Research Hospital (SJCRH), University of
Tennessee, Memphis, USA and approved by the Human Subjects
Committee at SJHCRH. The trial objective was to assess the
eEicacy of TENS for managing pain in people with SCD. The trial
was concluded aJer completion of 60 episodes of treatment (22
participants). The trial was described as cross-over; however, at
the first visit, participants were stratified on a self-reported pain
severity score (four categories) and randomised to treatment or
control (within these blocks), subsequent pain crises of the same
severity in a participant led to cross-over by giving the opposite
regimen of the previous one, whereas for those experiencing
an episode of a diEerent severity, it is not clear from the
paper whether these were re-randomised or given the alternate
treatment (regardless of pain grade).
Participants
22 people with SCD (20 Hb SS, I Hb SC, I Hb Sβº thalassaemia) were
included in this RCT. The age of the participants was between 12 to
27 years, with a median age of 17.5 years. Out of the 22 participants,
12 were female.
During initiation, participants were stratified into four groups
according to pain severity grade based on their pain score rating
(visual analogue scale from 0 to 10, with 10 being the severest pain
the participant had ever experienced), relief from analgesic and the
need for hospitalisations. If participants had pain at multiple sites,
the site with the maximum pain was taken into consideration.
Following allocation of treatment group, the assigned treatment
(either TENS or sham TENS) was initiated and continued for at least
four hours. In the TENS group, at the one-hour time point, there
was one missing response regarding improvement in pain rating
and at the four-hour time point there were three missing responses.
The control group (sham TENS) had only two missing responses at
the end of four hours. At the end of the trial period, four responses
were missing from the TENS group and five were missing from the
placebo group regarding overall value of TENS.
Interventions
The intervention device was a battery-powered Mentor 100 Dual
Channel TENS apparatus (Mentor Corporation, Minneapolis, Minn.)
using electrical impulses. The rate and width of each electrical
impulse, along with the amplitude, was adjustable. The distal
electrode was applied at the area of maximum pain within each
painful area or over a trigger point in the involved area as indicated
on a reference map of pain pathways (TENS Chart, Med General,
Inc., Minneapolis, Minn.). If the pain was confined to an extremity or
small area, the proximal electrode was placed over a trigger point
or along a pain pathway within the involved dermatome. If the pain
was reported in the back, chest or abdomen, the electrode was
placed over the paravertebral dorsal nerve root corresponding to
the pain dermatome(s). The TENS unit was switched on only aJer
randomisation. If the participant was allocated to the TENS group
then the settings were set at the original levels while for control it
was set at zero. In order to ensure blinding for both the participant
and the assessor, the assistant covered the machine's indicator
light and control with tape.
Outcomes
Outcomes included change in pain rating (VAS) aJer one hour
and four hours of either intervention or sham treatment. Other
outcomes analysed were the use of analgesics up to one hour and
up to four hours, as well as the participant's assessment of the
overall value of TENS. Adverse outcomes were reported.
Excluded studies
Trials were excluded at the full-text stage if they did not match
the inclusion criteria, or if they matched specific exclusion criteria.
Reasons for exclusion were as follows: 14 articles did not describe
RCTs or quasi-RCTs; five articles did not include TENS among the
interventions tested; and three trials did not use an experimental
study design.
Risk of bias in included studies
Please refer to the risk of bias graph,where we have included our
judgements about each risk of bias item presented as percentages
across all included studies (Figure 2).
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages




The trial authors reported that when a participant entered
the trial, stratification by four severity 'grades’, was performed.
Randomisation was carried out by an assistant using
"randomisation cards", but it was not clear how the randomisation
sequence was generated. It was reported that if individuals
returned for a subsequent visit and were assessed as having the
same severity grade of pain, then the participant was automatically
crossed over to the alternative treatment group. It is not clear from
the paper whether participants returning with a diEerent severity
grade of pain, were re-randomised or given the alternate treatment
(regardless of pain grade). We have therefore assessed the trial as
having a high risk of bias for this domain.
Allocation concealment
The double-blind randomisation was carried out by an 'assistant',
using randomisation cards for each severity grade. We have




If the participant was assigned to ‘TENS’, the assistant reset the
amplitude settings on the TENS device to their original levels. If the
card indicated ‘placebo’, the settings were leJ at zero.The assistant
covered the machine's indicator light and control with tape so that
the participant remained unaware about the assignment. However,
the assistant who was doing the allocation was also performing the
intervention (resetting the TENS machine). Therefore, we assessed
this domain as having an unclear risk of bias.
Outcome assessor
The assistant covered the machine’s indicator light and control
with tape so that the investigator remained unaware about the
assignment. We therefore assessed this domain as having a low risk
of bias.
Incomplete outcome data
From the available data there was a less than 15% attrition rate
among the participants. Therefore, we consider attrition bias to be
of low risk.
Selective reporting
The trial protocol was supplied on request from the authors. Some
outcome variables reported in the protocol (days of hospitalisation,
days of missed school or work) are not reported in the final results,
leading to selective reporting. Based on the largely null outcomes
reported we assume that reporting of these missing outcomes
may not have aEected the conclusion about eEicacy of TENS in
managing pain in people with SCD. Thus we regarded that the risk
of bias due to selective reporting was low.
Other potential sources of bias
The included trial is at a high risk for other potential sources
of bias. The number of participants allocated to the control and
intervention groups are not clearly stated. Although the trial is of
cross-over design, the number of participants crossed over during
the trial is also not clearly stated. The unit of analysis in the trial
is the pain episode rather than individual participant; whereas the
analysis has been done in the terms of participants, making the
statements conflicting.
E>ects of interventions
See: Summary of findings for the main comparison
The included trial compared TENS with placebo (sham) TENS. Prior
to randomisation of the participants the TENS machine was turned
on to produce a tingling sensation followed by a mild discomfort
when the amplitude was then reduced. Later, aJer randomisation,
participants receiving the intervention received TENS within the
recommended range (approximately 100 Hz pulses per second and
the pulse width at 30 ps) while for those assigned to placebo the
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setting of the machine was turned to zero. To maintain participant
blinding, they were briefed that a tingling sensation may or may not
be felt.
The included cross-over trial did not present first-arm data and we
were unable to analyse any data from this trial, also whilst reporting
on 22 participants, data on 60 treatment episodes were presented
(30 for each treatment group). We have therefore only provided a
narrative report.
The quality of the evidence has been graded for those outcomes
included in the summary of findings table. For the definitions of
these gradings, please refer to the summary of findings tables
(Summary of findings for the main comparison).
Primary outcomes
1. Pain relief
We aimed to present data at two to four weeks and aJer four weeks
post intervention. For long-term usage (e.g. for a period of at least
one month) we planned to consider the outcome measures up to
three months. We also considered pain relief as moderate (at least
30% pain relief over baseline) or substantial (at least 50% pain relief
over baseline) as defined by IMMPACT guidelines (Dworkin 2008)
Our included trial did not report pain relief at two to four weeks post
intervention, there was also no long-term usage reported (Wang
1988).
2. Pain intensity
The included trial recorded pain intensity by VAS at one and four
hours post intervention (Wang 1988). No significant changes in the
pain intensity was noted between the TENS and placebo group at
the end of one hour (P = 0.30) and four hours (P = 0.69) (very low-
quality evidence).
3. Frequency of pain episodes
The unit of analysis was the pain crisis in a participant in this
trial. More than one pain crisis in a participant was treated as
an independent episode for analysis, hence the frequency of pain
episodes were not reported in the included trial.
Secondary outcomes
1. Changes in consumption of analgesic and opioids during pain
episodes
It was stated in the trial report that "the two groups were
similar in analgesic usage. Twelve patients (20%) required narcotic
analgesics before the 1-hour rating with no significant diEerence
between placebo (25%) and TENS (14%) (X2 = 1.07, P = 0.30). Thirty-
eight patients (63% required pain medication before the 4-hour
rating, again with no significant diEerence between placebo (66%)
and TENS (61%) (X2 = 0.16, p = 0.69)". We graded this as very-low
quality evidence.
2. Changes in QoL (as measured by a validated scale)
The included trial did not assess QoL using a validated scale. Only a
subjective overall feeling of satisfaction with the intervention was
reported and it was mainly related to the pain.
3. Ability to cope with the ADL
This was not assessed and not reported in the included trial.
4. Adverse e2ects of the intervention
Although one case of itching was reported in the TENS group in the
included trial, the site and nature of itching was not clearly stated.
Hence, it cannot be clearly attributed to adverse eEect of TENS. Two
people in the sham TENS group felt the intervention increased the
pain. We graded this as very-low quality evidence.
D I S C U S S I O N
Summary of main results
Considering the methodological deficiencies of the single included
trial, we conclude the evidence level to be of very low quality, due
to this, the true eEect could be substantially diEerent from that
reported. There was no evidence of diEerences between TENS and
sham TENS groups when they rated their pain on a VAS. There
was also no evidence of a diEerence in analgesic use between the
two intervention groups. No clear evidence of the adverse eEects
of TENS were identified. We had planned to assess pain relief
at two and four weeks post intervention, however, there was no
provision in the research design of the included trial to provide
such information. Similarly, as part of our secondary outcomes,
we wanted to include changes in QoL (assessed by a validated
scale) and ADL, neither of which were assessed in the included
trial. Therefore, we are uncertain whether TENS improves overall
satisfactions compared to sham TENS (very low-quality evidence).
Overall completeness and applicability of evidence
During the search, we found that there was a scarcity of RCTs using
TENS for managing pain in people with SCD. Only one trial was
identified. The trial included people diagnosed with SCD aged from
12 to 27 years. The quality of evidence of the trial was judged to be
very low due to both methodological deficiencies and incomplete
reporting. The trial evaluated one of our primary outcomes, pain
intensity during intervention with TENS. However, other primary
outcomes of this review, pain relief at the end of two and four weeks
as well as pain frequency during intervention was not reported
in this trial. Only one of our secondary outcomes of analgesic
usage was reported. The remaining secondary outcomes were
not evaluated. Therefore, we can conclude that there is limited
applicability of available evidence from the included trial for our
review.
Quality of the evidence
Overall, the quality of the evidence was rated as very low across
diEerent outcomes according to GRADE methodology (Summary
of findings for the main comparison). With only one included
trial we cannot draw any robust conclusions in relation to the
objectives of our review. The risk of bias assessments ranged
from low to high. Random sequence generation and allocation
concealment were judged to be of high risk due to incomplete
information provided by the trial authors. Apart from these, other
methodological limitations such as lack of paired data or first-arm
data for the cross-over design, reporting of the analysis as a parallel
design rather than a cross-over design, results in further lowering
the quality of evidence.
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However, the blinding of participants, personnel and outcome
assessors was performed adequately. The missing responses were
also less than 15%. Hence, performance, detection and attrition
bias of the included trial is concluded to be of low risk.
Potential biases in the review process
We carried out a comprehensive search under the expert guidance
of the Cochrane Cystic Fibrosis and Genetic Disorders Review
Group, across various databases including grey literature and
clinical trial registries. However, the search resulted in trials
published mainly in the English language only.
Two review authors independently assessed the trials for inclusion
and extracted data from the included trial using the standard data
collection form. Two other authors also assessed the risk of bias of
the included trial independently (with a third author as adjudicator
if necessary). Thus we tried to minimise bias in trial selection, data
collection, analysis and assessment of the risk of bias. In order to
reduce other potential sources of bias we requested and received
the raw data from the trial authors for further analysis.
Agreements and disagreements with other studies or
reviews
Our search revealed very few systematic reviews and individual
studies on the eEect of non-pharmacological interventions for pain
in SCD. However, TENS was not included in any one of them except
the included trial. Thus, there is no scope for comparison with
similar evidence.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
To date we could identify only one randomised controlled trial
using transcutaneous electrical nerve stimulation (TENS) for
managing pain in people with sickle cell disease (SCD) and we are
unable to conclude, with any confidence, that TENS is harmful or
beneficial for managing pain in people with SCD.
Implications for research
The vaso-occlusive pain crises and chronic pain conditions are the
most common cause of suEering of people with SCD. Apart from
pharmacotherapy, which has got its own limitations, evidence is
also sought for non-pharmacological interventions. TENS has been
widely used as one of such interventions for pain relief in various
conditions. The literature reviewed so far as well as the included
trial in this review has shown no evidence of eEect of TENS in
managing pain in people with SCD. Although, the included trial
has reported overall satisfaction with TENS among people with
SCD, the quality of available evidence is judged to be of very low
quality due to poor methodological and reporting issues. Future
well-designed RCTs are required to assess the eEect of TENS on
managing pain in this population.
Earlier studies have shown that the presentation of SCD pain
manifestations varies in diEerent age groups. Children have been
seen to have longer pain-free intervals than adults with SCD (Ballas
2012). Thus, to eliminate age as a confounding factor, further
research on eEect of TENS in managing pain in SCD should be
analysed in subgroups related to age, e.g. among children and
adults.
To date, research has shown that the methods to produce placebo
or sham TENS do not produce the stimulation like the one produced
by a standardised TENS machine. This makes the participant
blinding ineEective if trial participants can identify the diEerence
between the two (Sluka 2013). Further research may be justified
in using a sham TENS machine that produces physical stimuli like
a standardised TENS machine but does not produce any electrical
impulse. Based on the recent advances in pathophysiology of acute
painful crises in SCD (Ballas 2005), adequate analgesia along with
other interventions for prevention of vaso-occlusion given at the
prodromal phase may abort the pain crises (Ballas 2012). Therefore,
future research of TENS for managing pain in SCD may focus on the
prodromal phase.
Aside from changes in pain intensity and analgesic usage, outcome
measures should also include pain relief in terms of moderate (30%
above baseline) or substantial (50% above baseline) according
to the IMMPACT guidelines (Dworkin 2008). The included trial
has reported ‘overall satisfaction’ for TENS. In future, overall
satisfaction eEects should be measured using a standardised
scale like Patient Global Impression of Change (PGIC) or Acute
Pain Management Service (APMS) which will be able to quantify
the patient satisfaction making statistical inference possible.
Assessment of eEects of TENS on quality of life and activities of daily
living should also be included in future research.
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Methods Described as a randomised double blind cross-over trial. However, cross-over was only performed for
those participants having a pain crisis of the same severity in their subsequent visit. It is unclear how
participants, who returned with a different severity of pain, were allocated to treatment group.
Participants 22 people with SCD (12 female and 10 male).
Age (12 to 27 years).
Interventions TENS versus 'sham' TENS.
Outcomes Pain ratings as assessed by the VAS, analgesic medication usage and overall patient evaluation.
Notes The authors graded the participants into four groups according to the severity of pain and reported 60
treatment episodes for the 22 participants.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk The trial authors reported that when a participant entered the trial, stratifica-
tion by 4 severity 'grades’, was performed. Randomisation was carried out by
an assistant (page 100) using randomised cards, but it was not clear how the
randomisation sequence was generated.
It was reported that if individuals returned for a subsequent visit and were as-
sessed as having the same severity grade of pain, then the participant was au-
tomatically crossed over to the alternative treatment group. It is not clear from
the paper whether participants returning with a different severity grade of




High risk The double-blind randomisation was carried out by an 'assistant', using ran-





Unclear risk If a participant was assigned to the ‘TENS’ treatment, the assistant reset the
TENS device to the original level. If the card read ‘Placebo’ then settings were
leJ at zero. The assistant covered the machine’s indicator light and control
with tape so that the patient remained unaware about the assignment. The as-
sistant who was doing the allocation was also performing the intervention (re-
setting the TENS machine).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk The assistant covered the machine’s indicator light and control with tape so




Low risk The trial was concluded and data analysed when 60 trials were completed. In
some of the tables, missing responses caused the total to be below 60.




Low risk The protocol was acquired from the authors on request. Certain outcome vari-
ables reported in the protocol, such as, days of hospitalisation, days of missed
school or work, were not reported in the final results. However, looking into
the majority null results reported by the trial, the non-reporting of the above-
mentioned outcomes may not have any impact on the conclusion or effect of
TENS in managing pain in SCD.
Wang 1988 
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Other bias High risk The number of participants allotted to control and intervention group were
not clearly stated.
The initial and final pain scores at the beginning and end of 1 and 4 hours were
not given. We have requested for the actual pain ratings at the beginning and
at the end of 1 and 4 hours of intervention from the author.
In addition, the trial involved a total of 22 participants and 60 pain episodes. If
a participant had pain in multiple sites, a separate pain rating was determined
for each area. The site of most severe pain was used in the analysis. Thus, their
unit of analysis in the report is pain episode rather than individuals. However it
is reported as "Twelve patients (20%) required narcotic analgesics before the
1-hour rating with no significant difference between placebo (25%) and TENS
(14%) (x2 = 1.07, p = 0.30). Thirty-eight patients (63%) required pain medica-
tion before the 4-hour rating". The statements are conflicting.
Wang 1988  (Continued)
SCD: sickle cell disease
TENS: transcutaneous electrical nerve stimulation
VAS: visual analogue scale
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Al-Dabbous 2014 Intervention not TENS
Anie 2002 Intervention not TENS
Ballas 2005 Article type not original trial
Ballas 2007 Article type not original trial
Elander 1996 Article type not original trial
Ely 2008 Intervention not TENS
Homi 1981 Intervention not TENS
Jacob 2001 Article type not original trial
Johnson 2008 Article type not original study
Myers 1999 Intervention not TENS
NHLBI 2002 Article type not original trial
NHLBI 2014a Article type not original trial
NHLBI 2014b Article type not original trial
Pegelow 1992 Study design not experimental
Pollack 1991 Study design not experimental
Rees 2003 Article type not original trial
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Study Reason for exclusion
Shapiro 1989 Article type not original study
Smith 2011 Study design not experimental
Steinberg 2011 Article type not original trial
Stinson 2003 Article type not original trial
Zempsky 2010 Article type not original trial
TENS: transcutaneous electrical nerve stimulation
 
 




Afferent input Information from our sensory organs (e.g. eye, skin) transmitted as input to the central nervous
system (brain, spinal cord).
Avascular necrosis Cellular death of bone components due to interruption of the blood supply; the bone structures
then collapse, resulting in bone destruction, pain, and loss of joint function.
Endogenous Originating or developing from within the body.
Haemolysis The destruction of red blood cells which leads to the release of hemoglobin from within the red
blood cells into the blood plasma.
Hypersplenism A condition in which the spleen becomes increasingly active and then rapidly removes the blood
cells.
Neuropathic Due to disease of nerves.
Nociceptive Of, relating to, or denoting, pain arising from the stimulation of nerve cells (often as distinct from
that arising from damage or disease in the nerves themselves).
Non-invasive Not requiring the introduction of instruments into the body.
Pharmacogenomics The use of human genetic variations to optimise the discovery and development of drugs and the
treatment of patients.
Presynaptic inhibition Refers to a decrease of transmitter release at central synapses.
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Database/ Resource Strategy
PubMed (1946 onwards) (sickle OR "Anemia, Sickle Cell"[Mesh]) AND ("Transcutaneous electric" OR "Transcutaneous elec-
trical" OR "Transcutaneous Electric Nerve Stimulation"[Mesh])
Embase (Ovid 1974 – to
present)
1 exp Sickle Cell Anemia/
2 sickle.tw.
3 1 OR 2
4 Transcutaneous electric* nerv* stimulation.tw.
5 TENS.tw.
6 Transcutaneous Electrical Nerve Stimulation/
7 (4 OR 5 OR 6)
8 (3 AND 7)
Clinicaltrials.gov [ADVANCED SEARCH]
STUDY TYPE: Interventional Studies
CONDITIONS: sickle
INTERVENTIONS: transcutaneous OR TENS
WHO ICTRP Two separate searches will be carried out:
SEARCH 1: sickle AND transcutaneous
SEARCH 2: sickle AND TENS
ISRCTN Registry [ADVANCED SEARCH]
CONDITION: sickle
INTERVENTIONS: transcutaneous OR TENS
Google Scholar sickle AND ("transcutaneous electric" OR "transcutaneous electrical" OR tens)
NOTE: The results will be sorted by “relevance” and the first 100 results screened for relevant stud-
ies
Grey Literature Databases Two separate searches of each database will be carried out:
SEARCH 1: sickle AND transcutaneous
SEARCH 2: sickle AND TENS
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